BRD3308
BRD3308 is a highly selective HDAC3 inhibitor with an IC50 of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC50 of 1.26 μM) or HDAC2 (IC50 of 1.34 μM) . BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency[1][2][3].
Product Specifications
CAS Number
1550053-02-5
UNSPSC
12352005
Hazard Statement
H315, H319
Target
Apoptosis; HDAC; HIV
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
COVID-19-anti-virus
Field of Research
Infection; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/brd3308.html
Purity
98.34
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(C)NC1=CC=C(C(NC2=CC=C(F)C=C2N)=O)C=C1
Molecular Formula
C15H14FN3O2
Molecular Weight
287.29
Precautions
H315, H319
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC1; HDAC2; HDAC3; HIV-1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Anti-PIWIL3 Antibody Picoband® APC Conjugated
Anti-Hsp27/HSPB1 Antibody Picoband® (FITC Conjugate)